Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Recently, Zacks.com users have been paying close attention to Tenet (THC). This makes it worthwhile to examine what the stock has in store.
Tenet Healthcare (THC) remains a compelling 'buy' due to strong growth, margin expansion, and deep undervaluation versus peers. THC's Ambulatory Care segment drives profitability, with nearly half of projected EBITDA from just 24% of revenue. Management has aggressively reduced leverage and repurchased $1.19B in stock, signaling balance sheet strength and shareholder alignment.
THC's 71.8% surge, lifted guidance and expanding outpatient reach fuel optimism, but valuation and policy risks pose lingering questions.
Tenet (THC) reported earnings 30 days ago. What's next for the stock?
Recently, Zacks.com users have been paying close attention to Tenet (THC). This makes it worthwhile to examine what the stock has in store.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
THC's Q3 profit beats estimates on higher revenues and strong segment growth, but rising costs drag shares lower.
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.